Simon О. Samokhin, Alexandr V. Patrushev, Yulia I. Akaeva, S. A. Parfenov, Gennadii G. Kutelev
Relevance. The last decade has seen significant progress in computer-aided image analysis and recognition, with modern computer-aided diagnostic algorithms not only catching up with, but in many aspects surpassing human abilities. At the heart of this breakthrough is the development of deep convolutional neural networks, which have given a new impetus to medical diagnosis, particularly of skin cancers. In this paper, we analyzed photo-based skin disease classification systems developed using algorithms based on deep learning convolutional neural networks. Such methods have been variously reported to enable automated diagnosis of skin neoplasms with high sensitivity and specificity. A disease that requires more detailed analysis of graphic images - skin melanoma - was chosen as the main object of study. Early diagnosis of melanoma is of great socio-economic importance, as in this case the prognosis of patients is significantly improved. Objective. The aim of this work is to analyze the results of artificial intelligence (AI) applications in dermatology, especially in the context of early detection of skin melanoma. Materials and Methods. Scientific articles were searched in PubMed, Scopus and eLIBRARY databases using the keywords "convolutional neural networks", "skin cancer" and "artificial intelligence". The depth of the search was 10 years. The final analysis included 38 sources where the results of our own research were presented. The advantages of artificial intelligence methods for dermatologists were analyzed. Main results. Artificial intelligence can significantly assist dermatologists in developing visual neoplasm diagnosis skills and improve diagnostic accuracy. The use of AI to process dermatoscopic data in conjunction with the analysis of anamnestic and clinical information from medical records will reduce the burden on the healthcare system through correctly diagnosed benign skin tumors. All of this promises to have a significant impact on the future development of dermatovenerology.
{"title":"Early diagnosis of skin oncologic diseases using artificial intelligence technologies","authors":"Simon О. Samokhin, Alexandr V. Patrushev, Yulia I. Akaeva, S. A. Parfenov, Gennadii G. Kutelev","doi":"10.25208/vdv16746","DOIUrl":"https://doi.org/10.25208/vdv16746","url":null,"abstract":"Relevance. The last decade has seen significant progress in computer-aided image analysis and recognition, with modern computer-aided diagnostic algorithms not only catching up with, but in many aspects surpassing human abilities. At the heart of this breakthrough is the development of deep convolutional neural networks, which have given a new impetus to medical diagnosis, particularly of skin cancers. In this paper, we analyzed photo-based skin disease classification systems developed using algorithms based on deep learning convolutional neural networks. Such methods have been variously reported to enable automated diagnosis of skin neoplasms with high sensitivity and specificity. A disease that requires more detailed analysis of graphic images - skin melanoma - was chosen as the main object of study. Early diagnosis of melanoma is of great socio-economic importance, as in this case the prognosis of patients is significantly improved. \u0000Objective. The aim of this work is to analyze the results of artificial intelligence (AI) applications in dermatology, especially in the context of early detection of skin melanoma. \u0000Materials and Methods. Scientific articles were searched in PubMed, Scopus and eLIBRARY databases using the keywords \"convolutional neural networks\", \"skin cancer\" and \"artificial intelligence\". The depth of the search was 10 years. The final analysis included 38 sources where the results of our own research were presented. The advantages of artificial intelligence methods for dermatologists were analyzed. \u0000Main results. Artificial intelligence can significantly assist dermatologists in developing visual neoplasm diagnosis skills and improve diagnostic accuracy. The use of AI to process dermatoscopic data in conjunction with the analysis of anamnestic and clinical information from medical records will reduce the burden on the healthcare system through correctly diagnosed benign skin tumors. All of this promises to have a significant impact on the future development of dermatovenerology.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"661 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140446154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Kovaleva, Igor Viktorovich Kazantsev, Annetta Akhmedovna Aibazova, Ekaterina Olegovna Ovchinnikova, Anastasia Pavlovna Shabaldina, Anastasia Alexandrovna Garina
Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using il-17 anticytokine therapy, started in the early stages of disease progression. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.
{"title":"Early anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis","authors":"J. Kovaleva, Igor Viktorovich Kazantsev, Annetta Akhmedovna Aibazova, Ekaterina Olegovna Ovchinnikova, Anastasia Pavlovna Shabaldina, Anastasia Alexandrovna Garina","doi":"10.25208/vdv15341","DOIUrl":"https://doi.org/10.25208/vdv15341","url":null,"abstract":"Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using il-17 anticytokine therapy, started in the early stages of disease progression. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"21 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139776467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Sorokina, Evgene Kalinichenko, I. Bisheva, Vera Stolpnikova
Psoriasis is a frequently occurring inflammatory skin disease. Fundamental research into the pathogenesis of psoriasis has significantly expanded our understanding of skin immunology, which has enabled the introduction of innovative and highly effective therapies. Psoriasis is a largely T-lymphocyte-mediated disease in which activation of innate immune cells and pathogenic T cells leads to inflammation and hyperproliferation of keratinocytes. Langerhans cells (LCs) like dendritic cells (DCs), which play an important role in the immune system, are mainly distributed in the epidermis. Since human and mouse skin DC subpopulations share common ontogenetic characteristics, we can further investigate the role of DCs in psoriatic inflammation in mice. T cells are an unconventional population of T lymphocytes that play an indispensable role in host defense, immune surveillance, and immune system homeostasis. Although T cells constitute only a small fraction of the total T cell pool, emerging evidence suggests that aberrantly activated T cells may play a role in the pathogenesis of psoriasis. Dermal T cells are the major IL-17-producing cells in the skin that respond to IL-23 stimulation. In addition, T cells have characteristics of memory cells that mediate repeated episodes of psoriatic inflammation. This review discusses the mechanisms by which Langerhans cells and T cells participate in the pathogenesis of psoriasis.
银屑病是一种常见的炎症性皮肤病。对银屑病发病机理的基础研究极大地扩展了我们对皮肤免疫学的认识，从而使创新和高效疗法得以问世。银屑病主要是一种由 T 淋巴细胞介导的疾病，先天性免疫细胞和致病性 T 细胞的活化导致炎症和角质形成细胞的过度增殖。在免疫系统中发挥重要作用的朗格汉斯细胞（Langerhans cells，LCs）与树突状细胞（DCs）一样，主要分布在表皮。由于人类和小鼠皮肤 DC 亚群具有共同的本体发育特征，我们可以进一步研究 DC 在小鼠银屑病炎症中的作用。T 细胞是一种非常规的 T 淋巴细胞群，在宿主防御、免疫监视和免疫系统平衡中发挥着不可或缺的作用。虽然 T 细胞只占整个 T 细胞库的一小部分，但新出现的证据表明，异常活化的 T 细胞可能在银屑病的发病机制中发挥作用。皮肤 T 细胞是皮肤中产生 IL-17 的主要细胞，能对 IL-23 的刺激做出反应。此外，T 细胞还具有记忆细胞的特征，可介导银屑病炎症的反复发作。本综述将讨论朗格汉斯细胞和 T 细胞参与银屑病发病机制的机制。
{"title":"LANGERHANS CELLS AND GAMMA DELTA LYMPHOCYTES IN THE PATHOGENESIS OF PSORIASIS","authors":"E. Sorokina, Evgene Kalinichenko, I. Bisheva, Vera Stolpnikova","doi":"10.25208/vdv14875","DOIUrl":"https://doi.org/10.25208/vdv14875","url":null,"abstract":"Psoriasis is a frequently occurring inflammatory skin disease. Fundamental research into the pathogenesis of psoriasis has significantly expanded our understanding of skin immunology, which has enabled the introduction of innovative and highly effective therapies. Psoriasis is a largely T-lymphocyte-mediated disease in which activation of innate immune cells and pathogenic T cells leads to inflammation and hyperproliferation of keratinocytes. Langerhans cells (LCs) like dendritic cells (DCs), which play an important role in the immune system, are mainly distributed in the epidermis. Since human and mouse skin DC subpopulations share common ontogenetic characteristics, we can further investigate the role of DCs in psoriatic inflammation in mice. T cells are an unconventional population of T lymphocytes that play an indispensable role in host defense, immune surveillance, and immune system homeostasis. Although T cells constitute only a small fraction of the total T cell pool, emerging evidence suggests that aberrantly activated T cells may play a role in the pathogenesis of psoriasis. Dermal T cells are the major IL-17-producing cells in the skin that respond to IL-23 stimulation. In addition, T cells have characteristics of memory cells that mediate repeated episodes of psoriatic inflammation. This review discusses the mechanisms by which Langerhans cells and T cells participate in the pathogenesis of psoriasis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"42 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139836450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Sorokina, Evgene Kalinichenko, I. Bisheva, Vera Stolpnikova
Psoriasis is a frequently occurring inflammatory skin disease. Fundamental research into the pathogenesis of psoriasis has significantly expanded our understanding of skin immunology, which has enabled the introduction of innovative and highly effective therapies. Psoriasis is a largely T-lymphocyte-mediated disease in which activation of innate immune cells and pathogenic T cells leads to inflammation and hyperproliferation of keratinocytes. Langerhans cells (LCs) like dendritic cells (DCs), which play an important role in the immune system, are mainly distributed in the epidermis. Since human and mouse skin DC subpopulations share common ontogenetic characteristics, we can further investigate the role of DCs in psoriatic inflammation in mice. T cells are an unconventional population of T lymphocytes that play an indispensable role in host defense, immune surveillance, and immune system homeostasis. Although T cells constitute only a small fraction of the total T cell pool, emerging evidence suggests that aberrantly activated T cells may play a role in the pathogenesis of psoriasis. Dermal T cells are the major IL-17-producing cells in the skin that respond to IL-23 stimulation. In addition, T cells have characteristics of memory cells that mediate repeated episodes of psoriatic inflammation. This review discusses the mechanisms by which Langerhans cells and T cells participate in the pathogenesis of psoriasis.
银屑病是一种常见的炎症性皮肤病。对银屑病发病机理的基础研究极大地扩展了我们对皮肤免疫学的认识，从而使创新和高效疗法得以问世。银屑病主要是一种由 T 淋巴细胞介导的疾病，先天性免疫细胞和致病性 T 细胞的活化导致炎症和角质形成细胞的过度增殖。在免疫系统中发挥重要作用的朗格汉斯细胞（Langerhans cells，LCs）与树突状细胞（DCs）一样，主要分布在表皮。由于人类和小鼠皮肤 DC 亚群具有共同的本体发育特征，我们可以进一步研究 DC 在小鼠银屑病炎症中的作用。T 细胞是一种非常规的 T 淋巴细胞群，在宿主防御、免疫监视和免疫系统平衡中发挥着不可或缺的作用。虽然 T 细胞只占整个 T 细胞库的一小部分，但新出现的证据表明，异常活化的 T 细胞可能在银屑病的发病机制中发挥作用。皮肤 T 细胞是皮肤中产生 IL-17 的主要细胞，能对 IL-23 的刺激做出反应。此外，T 细胞还具有记忆细胞的特征，可介导银屑病炎症的反复发作。本综述将讨论朗格汉斯细胞和 T 细胞参与银屑病发病机制的机制。
{"title":"LANGERHANS CELLS AND GAMMA DELTA LYMPHOCYTES IN THE PATHOGENESIS OF PSORIASIS","authors":"E. Sorokina, Evgene Kalinichenko, I. Bisheva, Vera Stolpnikova","doi":"10.25208/vdv14875","DOIUrl":"https://doi.org/10.25208/vdv14875","url":null,"abstract":"Psoriasis is a frequently occurring inflammatory skin disease. Fundamental research into the pathogenesis of psoriasis has significantly expanded our understanding of skin immunology, which has enabled the introduction of innovative and highly effective therapies. Psoriasis is a largely T-lymphocyte-mediated disease in which activation of innate immune cells and pathogenic T cells leads to inflammation and hyperproliferation of keratinocytes. Langerhans cells (LCs) like dendritic cells (DCs), which play an important role in the immune system, are mainly distributed in the epidermis. Since human and mouse skin DC subpopulations share common ontogenetic characteristics, we can further investigate the role of DCs in psoriatic inflammation in mice. T cells are an unconventional population of T lymphocytes that play an indispensable role in host defense, immune surveillance, and immune system homeostasis. Although T cells constitute only a small fraction of the total T cell pool, emerging evidence suggests that aberrantly activated T cells may play a role in the pathogenesis of psoriasis. Dermal T cells are the major IL-17-producing cells in the skin that respond to IL-23 stimulation. In addition, T cells have characteristics of memory cells that mediate repeated episodes of psoriatic inflammation. This review discusses the mechanisms by which Langerhans cells and T cells participate in the pathogenesis of psoriasis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"98 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139776728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Katkhanova, Galina Nikolaevna Burtseva, Anastasia Vadimovna Solovyova
Background. Acne therapy is an urgent problem of dermatocosmetology. The clinical manifestations of dermatosis can be alleviated, and its long-term consequences can be prevented by early diagnosis and timely treatment, which affects all parts of the pathogenesis in a multifaceted way. The aim of the study was to compare the clinical efficacy and safety of the use of monotherapy of 0.1% adapalene cream (Adaklin) with combined external therapy of 0.1% adapalene cream (Adaklin) with 20% azelaic acid cream (Azix-Derm) in the treatment of mild to moderate acne. Methods. 50 patients aged 12 to 50 years with mild to moderate acne were under observation. Patients group 1 of observation (n = 16), were prescribed Adaklin cream, 1 time per day (evening) against the background of skin care. In the group 2 with mild to moderate papulo-pustular acne and post-inflammatory changes, patients were prescribed a combination of 0.1% adapalene cream and 20% azelaic acid cream Results. Total clinical remission after 6 months therapy was achieved in 70% of cases, a significant improvement in 28%.In group 1 clinical recovery was obtained in 48% of patients, a significant improvement in 50%, in patients from the group 2 clinical recovery was recorded in 58%, significant improvement in 36%; Combined treatment was able to achieve regression of dyschromia in 46% of patients, pseudoatorofy in 22%, which significantly improved the results of therapy and made it possible to achieve a good cosmetic effect. Conclusion. The combined use of drugs for external use of adapalene and AK in the treatment of papulo-pustular acne of mild and AK in the treatment of papulo-pustular acne of mild and moderate severity can significantly increase the effectiveness of treatment, achieve a stable clinical effect and remission of the disease, as well as improve the quality of life of patients.
{"title":"POSSIBILITIES OF USING TOPICAL RETINOIDS AND AZELAIC ACID IN ACNE THERAPY","authors":"O. Katkhanova, Galina Nikolaevna Burtseva, Anastasia Vadimovna Solovyova","doi":"10.25208/vdv11661","DOIUrl":"https://doi.org/10.25208/vdv11661","url":null,"abstract":"Background. \u0000Acne therapy is an urgent problem of dermatocosmetology. The clinical manifestations of dermatosis can be alleviated, and its long-term consequences can be prevented by early diagnosis and timely treatment, which affects all parts of the pathogenesis in a multifaceted way. \u0000The aim of the study was to compare the clinical efficacy and safety of the use of monotherapy of 0.1% adapalene cream (Adaklin) with combined external therapy of 0.1% adapalene cream (Adaklin) with 20% azelaic acid cream (Azix-Derm) in the treatment of mild to moderate acne. \u0000Methods. 50 patients aged 12 to 50 years with mild to moderate acne were under observation. Patients group 1 of observation (n = 16), were prescribed Adaklin cream, 1 time per day (evening) against the background of skin care. In the group 2 with mild to moderate papulo-pustular acne and post-inflammatory changes, patients were prescribed a combination of 0.1% adapalene cream and 20% azelaic acid cream \u0000Results. Total clinical remission after 6 months therapy was achieved in 70% of cases, a significant improvement in 28%.In group 1 clinical recovery was obtained in 48% of patients, a significant improvement in 50%, in patients from the group 2 clinical recovery was recorded in 58%, significant improvement in 36%; Combined treatment was able to achieve regression of dyschromia in 46% of patients, pseudoatorofy in 22%, which significantly improved the results of therapy and made it possible to achieve a good cosmetic effect. Conclusion. The combined use of drugs for external use of adapalene and AK in the treatment of papulo-pustular acne of mild and AK in the treatment of papulo-pustular acne of mild and moderate severity can significantly increase the effectiveness of treatment, achieve a stable clinical effect and remission of the disease, as well as improve the quality of life of patients.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139774072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Katkhanova, Galina Nikolaevna Burtseva, Anastasia Vadimovna Solovyova
Background. Acne therapy is an urgent problem of dermatocosmetology. The clinical manifestations of dermatosis can be alleviated, and its long-term consequences can be prevented by early diagnosis and timely treatment, which affects all parts of the pathogenesis in a multifaceted way. The aim of the study was to compare the clinical efficacy and safety of the use of monotherapy of 0.1% adapalene cream (Adaklin) with combined external therapy of 0.1% adapalene cream (Adaklin) with 20% azelaic acid cream (Azix-Derm) in the treatment of mild to moderate acne. Methods. 50 patients aged 12 to 50 years with mild to moderate acne were under observation. Patients group 1 of observation (n = 16), were prescribed Adaklin cream, 1 time per day (evening) against the background of skin care. In the group 2 with mild to moderate papulo-pustular acne and post-inflammatory changes, patients were prescribed a combination of 0.1% adapalene cream and 20% azelaic acid cream Results. Total clinical remission after 6 months therapy was achieved in 70% of cases, a significant improvement in 28%.In group 1 clinical recovery was obtained in 48% of patients, a significant improvement in 50%, in patients from the group 2 clinical recovery was recorded in 58%, significant improvement in 36%; Combined treatment was able to achieve regression of dyschromia in 46% of patients, pseudoatorofy in 22%, which significantly improved the results of therapy and made it possible to achieve a good cosmetic effect. Conclusion. The combined use of drugs for external use of adapalene and AK in the treatment of papulo-pustular acne of mild and AK in the treatment of papulo-pustular acne of mild and moderate severity can significantly increase the effectiveness of treatment, achieve a stable clinical effect and remission of the disease, as well as improve the quality of life of patients.
{"title":"POSSIBILITIES OF USING TOPICAL RETINOIDS AND AZELAIC ACID IN ACNE THERAPY","authors":"O. Katkhanova, Galina Nikolaevna Burtseva, Anastasia Vadimovna Solovyova","doi":"10.25208/vdv11661","DOIUrl":"https://doi.org/10.25208/vdv11661","url":null,"abstract":"Background. \u0000Acne therapy is an urgent problem of dermatocosmetology. The clinical manifestations of dermatosis can be alleviated, and its long-term consequences can be prevented by early diagnosis and timely treatment, which affects all parts of the pathogenesis in a multifaceted way. \u0000The aim of the study was to compare the clinical efficacy and safety of the use of monotherapy of 0.1% adapalene cream (Adaklin) with combined external therapy of 0.1% adapalene cream (Adaklin) with 20% azelaic acid cream (Azix-Derm) in the treatment of mild to moderate acne. \u0000Methods. 50 patients aged 12 to 50 years with mild to moderate acne were under observation. Patients group 1 of observation (n = 16), were prescribed Adaklin cream, 1 time per day (evening) against the background of skin care. In the group 2 with mild to moderate papulo-pustular acne and post-inflammatory changes, patients were prescribed a combination of 0.1% adapalene cream and 20% azelaic acid cream \u0000Results. Total clinical remission after 6 months therapy was achieved in 70% of cases, a significant improvement in 28%.In group 1 clinical recovery was obtained in 48% of patients, a significant improvement in 50%, in patients from the group 2 clinical recovery was recorded in 58%, significant improvement in 36%; Combined treatment was able to achieve regression of dyschromia in 46% of patients, pseudoatorofy in 22%, which significantly improved the results of therapy and made it possible to achieve a good cosmetic effect. Conclusion. The combined use of drugs for external use of adapalene and AK in the treatment of papulo-pustular acne of mild and AK in the treatment of papulo-pustular acne of mild and moderate severity can significantly increase the effectiveness of treatment, achieve a stable clinical effect and remission of the disease, as well as improve the quality of life of patients.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"172 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139833566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Kovaleva, Igor Viktorovich Kazantsev, Annetta Akhmedovna Aibazova, Ekaterina Olegovna Ovchinnikova, Anastasia Pavlovna Shabaldina, Anastasia Alexandrovna Garina
Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using il-17 anticytokine therapy, started in the early stages of disease progression. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.
{"title":"Early anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis","authors":"J. Kovaleva, Igor Viktorovich Kazantsev, Annetta Akhmedovna Aibazova, Ekaterina Olegovna Ovchinnikova, Anastasia Pavlovna Shabaldina, Anastasia Alexandrovna Garina","doi":"10.25208/vdv15341","DOIUrl":"https://doi.org/10.25208/vdv15341","url":null,"abstract":"Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using il-17 anticytokine therapy, started in the early stages of disease progression. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"237 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139835927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The functional role of sweating is not limited only to thermoregulation and excretion. There are other functions of it the ability to enhance and maintain hydration and barrier function of the skin. Excessive sweating can lead to an exacerbation or cause many skin diseases, form psychological discomfort in a person due to wet clothes or an accompanying unpleasant odor. Primary hyperhidrosis may be an autosomal dominant genetic disease. Secondary, usually generalized hyperhidrosis is often associated with drug effects on the body or a systemic disease. The following approaches are used in the treatment of hyperhidrosis: 1. blocking the release of sweat to the skin surface (aluminum salts and formaldehyde); 2. physiotherapy (iontophoresis); 3. destruction of sweat glands and cessation of sweat production (excision of a skin flap with subcutaneous fat, curettage, microwave technology, etc.); 4. termination of the signal from the central nervous system to the sweat glands (transthoracic endoscopic sympathectomy, percutaneous radiofrequency sympathectomy, botulinum toxin injections, systemic anticholinergic drugs). External remedies for excessive sweating include the Russian drug Formagel, containing 3.7% formaldehyde. This drug is a non-invasive, easily doable, effective, safe method of treating hyperhidrosis.
{"title":"Hyperhidrosis: problems and solutions","authors":"S. Petrova, V. Albanova, K. S. Guzev","doi":"10.25208/vdv11878","DOIUrl":"https://doi.org/10.25208/vdv11878","url":null,"abstract":"The functional role of sweating is not limited only to thermoregulation and excretion. There are other functions of it the ability to enhance and maintain hydration and barrier function of the skin. Excessive sweating can lead to an exacerbation or cause many skin diseases, form psychological discomfort in a person due to wet clothes or an accompanying unpleasant odor. Primary hyperhidrosis may be an autosomal dominant genetic disease. Secondary, usually generalized hyperhidrosis is often associated with drug effects on the body or a systemic disease. The following approaches are used in the treatment of hyperhidrosis: 1. blocking the release of sweat to the skin surface (aluminum salts and formaldehyde); 2. physiotherapy (iontophoresis); 3. destruction of sweat glands and cessation of sweat production (excision of a skin flap with subcutaneous fat, curettage, microwave technology, etc.); 4. termination of the signal from the central nervous system to the sweat glands (transthoracic endoscopic sympathectomy, percutaneous radiofrequency sympathectomy, botulinum toxin injections, systemic anticholinergic drugs). External remedies for excessive sweating include the Russian drug Formagel, containing 3.7% formaldehyde. This drug is a non-invasive, easily doable, effective, safe method of treating hyperhidrosis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":" 33","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139790862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The functional role of sweating is not limited only to thermoregulation and excretion. There are other functions of it the ability to enhance and maintain hydration and barrier function of the skin. Excessive sweating can lead to an exacerbation or cause many skin diseases, form psychological discomfort in a person due to wet clothes or an accompanying unpleasant odor. Primary hyperhidrosis may be an autosomal dominant genetic disease. Secondary, usually generalized hyperhidrosis is often associated with drug effects on the body or a systemic disease. The following approaches are used in the treatment of hyperhidrosis: 1. blocking the release of sweat to the skin surface (aluminum salts and formaldehyde); 2. physiotherapy (iontophoresis); 3. destruction of sweat glands and cessation of sweat production (excision of a skin flap with subcutaneous fat, curettage, microwave technology, etc.); 4. termination of the signal from the central nervous system to the sweat glands (transthoracic endoscopic sympathectomy, percutaneous radiofrequency sympathectomy, botulinum toxin injections, systemic anticholinergic drugs). External remedies for excessive sweating include the Russian drug Formagel, containing 3.7% formaldehyde. This drug is a non-invasive, easily doable, effective, safe method of treating hyperhidrosis.
{"title":"Hyperhidrosis: problems and solutions","authors":"S. Petrova, V. Albanova, K. S. Guzev","doi":"10.25208/vdv11878","DOIUrl":"https://doi.org/10.25208/vdv11878","url":null,"abstract":"The functional role of sweating is not limited only to thermoregulation and excretion. There are other functions of it the ability to enhance and maintain hydration and barrier function of the skin. Excessive sweating can lead to an exacerbation or cause many skin diseases, form psychological discomfort in a person due to wet clothes or an accompanying unpleasant odor. Primary hyperhidrosis may be an autosomal dominant genetic disease. Secondary, usually generalized hyperhidrosis is often associated with drug effects on the body or a systemic disease. The following approaches are used in the treatment of hyperhidrosis: 1. blocking the release of sweat to the skin surface (aluminum salts and formaldehyde); 2. physiotherapy (iontophoresis); 3. destruction of sweat glands and cessation of sweat production (excision of a skin flap with subcutaneous fat, curettage, microwave technology, etc.); 4. termination of the signal from the central nervous system to the sweat glands (transthoracic endoscopic sympathectomy, percutaneous radiofrequency sympathectomy, botulinum toxin injections, systemic anticholinergic drugs). External remedies for excessive sweating include the Russian drug Formagel, containing 3.7% formaldehyde. This drug is a non-invasive, easily doable, effective, safe method of treating hyperhidrosis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"107 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139850754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. G. Artamonova, A. Karamova, A. Kubanov, V. Chikin, E. Monchakovskaya
Epidermolysis bullosa is a group of rare hereditary skin diseases based on mutations in the genes of structural proteins of the epidermis and the dermal-epidermal junction. Clinically, epidermolysis bullosa is characterized by the appearance of erosions and blisters on the skin and mucous membranes in response to any minor impact. Currently, the treatment of epidermolysis bullosa is only symptomatic. Pathogenetic methods of the epidermolysis bullosa therapy are under development. One of the new possible pathogenetic directions in the treatment of epidermolysis bullosa is aminoglycoside antibiotics (gentamicin, geneticin, paromomycin). A number of studies have shown the ability of gentamicin to promote readthrough terminating codon and resume the synthesis of type VII collagen in keratinocytes and fibroblasts in patients with epidermolysis bullosa with nonsense mutations in the COL7A1. The review presented the possibilities of gentamicin therapy for patients with epidermolysis bullosa, describes the mechanism of its action, summarizes data from clinical trials.
{"title":"Deficient skin proteins rescue of expression in patients with epidermolysis bullosa: efficacy of gentamicin","authors":"O. G. Artamonova, A. Karamova, A. Kubanov, V. Chikin, E. Monchakovskaya","doi":"10.25208/vdv16737","DOIUrl":"https://doi.org/10.25208/vdv16737","url":null,"abstract":"Epidermolysis bullosa is a group of rare hereditary skin diseases based on mutations in the genes of structural proteins of the epidermis and the dermal-epidermal junction. Clinically, epidermolysis bullosa is characterized by the appearance of erosions and blisters on the skin and mucous membranes in response to any minor impact. Currently, the treatment of epidermolysis bullosa is only symptomatic. Pathogenetic methods of the epidermolysis bullosa therapy are under development. One of the new possible pathogenetic directions in the treatment of epidermolysis bullosa is aminoglycoside antibiotics (gentamicin, geneticin, paromomycin). A number of studies have shown the ability of gentamicin to promote readthrough terminating codon and resume the synthesis of type VII collagen in keratinocytes and fibroblasts in patients with epidermolysis bullosa with nonsense mutations in the COL7A1. The review presented the possibilities of gentamicin therapy for patients with epidermolysis bullosa, describes the mechanism of its action, summarizes data from clinical trials.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139788518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：